Volume Alert: Insmed may be active after Phase II trial result (INSM)

Posted in General 
June 25th, 2009

Insmed Inc. (Nasdaq: INSM) announced this morning that its IPLEX candidate for treating muscular dystrophy did not show a statistically significant improvement in the functional measure of endurance in a Phase II trial. Shares were halted just before 8 a.m. Eastern this morning, pending the announcement.

Comments are closed